50
Participants
Start Date
November 30, 2006
Primary Completion Date
June 30, 2008
Study Completion Date
September 30, 2008
ATN-224
ATN-224 high dose: 300mg ATN-224 low dose: 30mg
Memorial Sloan Kettering Cancer Center, New York
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison
University of Texas MD Anderson Cancer Center, Houston
University of California San Francisco, San Francisco
Oregon Health and Science University, Portland
Lead Sponsor
Prostate Cancer Clinical Trials Consortium
OTHER
Attenuon
INDUSTRY